Cisplatin: mode of cytotoxic action and molecular basis of resistance
The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Abstract
Cisplatin is one of the most potent antitumor agents known, displaying clinical activity against a wide variety of solid tumors. Its cytotoxic mode of action is mediated by its interaction with DNA to form DNA adducts, primarily intrastrand crosslink adducts, which activate several signal transduction pathways, including those involving ATR, p53, p73, and MAPK, and culminate in the activation of apoptosis. DNA damage-mediated apoptotic signals, however, can be attenuated, and the resistance that ensues is a major limitation of cisplatin-based chemotherapy. The mechanisms responsible for cisplatin resistance are several, and contribute to the multifactorial nature of the problem. Resistance mechanisms that limit the extent of DNA damage include reduced drug uptake, increased drug inactivation, and increased DNA adduct repair. Origins of these pharmacologic-based mechanisms, however, are at the molecular level. Mechanisms that inhibit propagation of the DNA damage signal to the apoptotic machinery include loss of damage recognition, overexpression of HER-2/neu, activation of the PI3-K/Akt (also known as PI3-K/PKB) pathway, loss of p53 function, overexpression of antiapoptotic bcl-2, and interference in caspase activation. The molecular signature defining the resistant phenotype varies between tumors, and the number of resistance mechanisms activated in response to selection pressures dictates the overall extent of cisplatin resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ATM kinase seems to be activated primarily in response to the induction of double-strand breaks whereas ATR is critical for cellular checkpoint responses to stalled replication forks and to many types of DNA damage, such as those induced by UV light and cisplatin (16,17).”
In the citing paper
“Clinical use of cisplatin is complicated by the dose-limiting side effects as well as rapid development of drug resistance [5].”
Citations
Cites
1 retracted
BRCA1 required for transcription-coupled repair of oxidative DNA damage
Gowen, L. C., Avrutskaya, A. V., Latour, A. M., Koller, B. H., & Leadon, S. A. (1998) · Science · doi:10.1126/science.281.5379.1009 · Cited by 496
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×
“A major factor affecting the loss of apoptotic function is p53 gene mutation (see Figure 6), which is observed in about a half of all cancers (Hollstein et al., 1991; Soussi, 2000).”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Bcl-2 functions in an antioxidant pathway to prevent apoptosis
Hockenbery, D. M., Oltvai, Z. N., Yin, X.-M., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80066-n · Cited by 3,419
Hartwell, L. H., & Kastan, M. B. (1994) · Science · doi:10.1126/science.7997877 · Cited by 2,535
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · cited 2×
“Intracellular factors that may inhibit such an activation of p53 include overexpression of the negative feedback regulator Mdm2 and downregulation of the moderator of Mdm2, p14ARF (Fritsche et al., 1993; Shieh et al., 1997; Lakin and Jackson, 1999; Meek, 1999; Deng et al., 2002).”
BackgroundA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“…resistance-associated (MRP) gene family, composed of at least seven members (MRP1–7), has been a major target of investigations, primarily as several of these ABC membrane proteins have been found in tumor cells and associated with cellular efflux of a variety of drugs (Borst et al., 2000).”
Background
Research works printed but not linked: 5
- Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ and Kaufmann SH. (1997). Blood, 90, 935–943. · doi:10.1182/blood.v90.3.935.935_935_943 · Paper page
- Eisenhauer E, Swerton K, Sturgeon J, Fine S, O'Reilly S and Canetta R . (1990). Carboplatin: Current Perspectives and Future Directions. Bunn P, Canetta R, Ozols R and Rozencweig M (eds). WB Saunders Company: Philadelphia, PA, pp. 133–140.
- He G and Siddik ZH . (2001). Proc. Am. Assoc. Cancer Res., 42, 901.
- Holford J, Rogers P and Kelland LR . (1998). Int. J. Cancer, 77, 94–100. · doi:10.1002/(sici)1097-0215(19980703)77:1<94::aid-ijc15>3.0.co;2-9
- Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W and Press MF . (2001). Clin. Cancer Res., 7, 2984–2997.
Cited by
Items 901–1,000 of 1,004
Improving chemoradiation efficacy by PI3-K/AKT inhibition
Stegeman, H., Span, P. N., Kaanders, J. H. A. M., & Bussink, J. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.09.005 · Cited by 51
“synthase kinase-3 beta (GSK-3b) blocks the negative regulation of this protein on variou proliferation, and reduction of apoptosis [19,33].”
BackgroundMin, J., Stegner, A. L., Alexander, H., & Alexander, S. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.3.795-805.2004 · Cited by 46
Downregulation of vimentin expression increased drug resistance in ovarian cancer cells
Huo, Y., Zheng, Z., Chen, Y., Wang, Q., Zhang, Z., & Deng, H. (2016) · Oncotarget · doi:10.18632/oncotarget.9970 · Cited by 50
“Platinum-based drug resistance in ovarian cancer has been attributed to many factors including intracellular cisplatin inactivation, reduced intracellular drug accumulation, increased DNA repair and defects in cell death signaling pathways [4].”
BackgroundYang, J., Zhang, K., Wu, J. H., Shi, J., Xue, J., Li, J., Chen, J., Zhu, Y., Wei, J., He, J., et al. (2016) · Stem Cells International · doi:10.1155/2016/1690896 · Cited by 57
“Cisplatin-based chemotherapy is the first-line therapy for advanced NSCLC, which is based on the formation of cisplatin-DNA that leads to DNA damage and sequentially activates apoptosis signaling pathways in cells [6].”
Synergistic antitumor effect of combined paclitaxel with FEN1 inhibitor in cervical cancer cells
He, L., Yang, H., Zhou, S., Zhu, H., Mao, H., Ma, Z., Wu, T., Kumar, A. K., Kathera, C., Janardhan, A., et al. (2018) · DNA repair · doi:10.1016/j.dnarep.2018.01.003 · Cited by 46
Dunne, M., Dou, Y. N., Drake, D. M., Spence, T., Gontijo, S. M. D. L., Wells, P. G., & Allen, C. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.029 · Cited by 50
Glucose-derived acetate and ACSS2 as key players in cisplatin resistance in bladder cancer
He, W., Lee, S.-J., Zhu, W., Lee, O.-J., Yun, S. J., Kim, J., & Park, S. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.06.005 · Cited by 50
Drug capture materials based on genomic DNA-functionalized magnetic nanoparticles
Blumenfeld, C. M., Schulz, M. D., Aboian, M., Wilson, M. W., Moore, T., Hetts, S. W., & Grubbs, R. H. (2018) · Nature Communications · doi:10.1038/s41467-018-05305-2 · Cited by 46
El‐Wekil, M. M., Darweesh, M. F., Shaykoon, M. S. A., & Ali, R. (2020) · Talanta · doi:10.1016/j.talanta.2020.121084 · Cited by 46
Nuclear ING2 expression is reduced in human cutaneous melanomas
Lu, F., Dai, D., Martinka, M., Ho, V., & Li, G. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603205 · Cited by 48
Zhong, Y., Chen, H., Tan, B., Yu, H., & Huang, X. (2013) · Oncology Letters · doi:10.3892/ol.2013.1524 · Cited by 48
Platinated Copper(3‐Clip‐Phen) Complexes as Effective DNA‐Cleaving and Cytotoxic Agents
Özalp‐Yaman, Ş., de Hoog, P., Amadei, G. A., Pitié, M., Gámez, P., Dewelle, J., Mijatovic, T., Meunier, B., Robert Kiss, A., & Reedijk, J. (2008) · Chemistry - A European Journal · doi:10.1002/chem.200702021 · Cited by 46
Mantovani, G., Bondioni, S., Lania, A. G., Rodolfo, M., Peverelli, E., Polentarutti, N., Rodriguez, T. V., Ferrero, S., Bòsari, S., Beck‐Peccoz, P., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210831 · Cited by 52
RetractedKapp, T., Dullin, A., & Gust, R. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050845r · Cited by 46
Agapov, A., Olina, A., & Kulbachinskiy, A. V. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac174 · Cited by 47
Sui, Q., Chen, Z., Hu, Z., Huang, Y., Liang, J., Bi, G., Bian, Y., Zhao, M., Zhan, C., Lin, Z., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03372-0 · Cited by 57
“For the mechanism of its pharmacology, generally, they damage DNA, leading to cell cycle arrest and cell death, typically via apoptosis [5, 6].”
BackgroundRepurposing FDA-approved drugs against the toxicity of platinum-based anticancer drugs
Famurewa, A. C., Mukherjee, A. G., Wanjari, U. R., Sukumar, A., Murali, R., Renu, K., Vellingiri, B., Dey, A., & Gopalakrishnan, A. V. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120789 · Cited by 48
Cai, L., Wang, Y., Chen, H., Tan, Y., Yang, T., Zhang, S., Guo, Z., & Wang, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00836 · Cited by 47
Becker, M. W., Müller, C. B., Bastiani, M. A. D., & Klamt, F. (2014) · PubMed · doi:10.14670/hh-29.21 · Cited by 45
Epigenomics and Ovarian Carcinoma
Maldonado, L., & Hoque, M. O. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.72 · Cited by 49
Kisova, A., Zerzánková, L., Habtemariam, A., Sadler, P. J., Brabec, V., & Kašpárková, J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200105d · Cited by 45
Dietary supplementation of flaxseed oil ameliorates the effect of cisplatin on rat kidney
Naqshbandi, A., Rizwan, S., & Khan, F. (2012) · Journal of Functional Foods · doi:10.1016/j.jff.2012.11.002 · Cited by 45
Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer
Yang, Y., Zhang, P., Zhao, Y., Yang, J., Jiang, G., & Fan, J. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1095405 · Cited by 45
Tsai, M., Weng, S., Kuo, Y., Chiu, Y., & Lin, Y. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.071316 · Cited by 46
Mezencev, R., Matyunina, L. V., Wagner, G. T., & McDonald, J. F. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.71 · Cited by 45
Molecular Mechanism of Drug Resistance
Ray, S., Das, S., & Suar, M. (2017) · Drug Resistance in Bacteria, Fungi, Malaria, and Cancer · doi:10.1007/978-3-319-48683-3_3 · Cited by 40
“ERCC1 (excision repair cross-complementing protein), a DNA-binding protein, has the ability to recognize cisplatin-induced DNA damage and thus its level increases in cisplatin-resistant cells (Siddik 2003).”
BackgroundJiang, Y., Ji, F., Liu, Y., He, M., Zhang, Z., Yang, J., Wang, N., Zhong, C., Jin, Q., Ye, X., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.6035 · Cited by 51
Rodríguez‐Fanjul, V., López‐Torres, E., Mendiola, M. A., & Pizarro, A. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.009 · Cited by 48
Søgaard, C. K., Blindheim, A., Røst, L. M., Petrović, V., Nepal, A., Bachke, S., Liabakk, N., Gederaas, O. A., Viset, T., Arum, C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25963 · Cited by 46
“Formation of DNA interstrand crosslinks are responsible for the major cytotoxicity of cisplatin, but increased DNA repair, overexpression of ERBB2 and activation of the PI3K/Akt pathway often contributes to development of cisplatin resistance [5].”
BackgroundBraga, C. B., Perli, G., Becher, T. B., & Ornelas, C. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00058 · Cited by 45
Ferrocenes as new anticancer drug candidates: Determination of the mechanism of action
Skoupilová, H., Bartošík, M., Sommerová, L., Pinkas, J., Vaculovič, T., Kanický, V., Karban, J., & Hrstka, R. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172825 · Cited by 49
Huang, H.-K., Lin, Y.-H., Chang, H.-A., Lai, Y., Chen, Y., Huang, S.-C., Chou, C.-Y., & Chiu, W. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00630-5 · Cited by 48
Ge, H., Du, J., Zheng, J., Xu, N., Yao, Q., Long, S., Fan, J., & Peng, X. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.137040 · Cited by 47
Hirose, A., SATO, E., Fujii, H., Sun, B., NISHIOKA, H., & Aruoma, O. I. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.03.031 · Cited by 45
Modification and Uptake of a Cisplatin Carbonato Complex by Jurkat Cells
Centerwall, C. R., Tacka, K. A., Kerwood, D. J., Goodisman, J., Toms, B. B., Dubowy, R. L., & Dabrowiak, J. C. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.023184 · Cited by 45
Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration
Wangpaichitr, M., Theodoropoulos, G., Nguyen, D. J. M., Wu, C., Spector, S. A., Feun, L. G., & Savaraj, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147379 · Cited by 47
“Cisplatin‐induced toxicity involves various mechanisms, such as DNA adduct formation, mitochondrial dysfunction, and oxidative stress [4] The majority of patients will initially respond to cisplatin treatment; however, resistance to cisplatin is inevitable.”
BackgroundTyagi, A., Kaushal, K., Chandrasekaran, A. P., Sarodaya, N., Das, S., Park, C., Hong, S., Kim, K.-S., & Ramakrishna, S. (2022) · Theranostics · doi:10.7150/thno.72826 · Cited by 52
“Several processes account for cisplatin resistance, including increased drug efflux, DNA-adduct repair, and activation of pro-survival and inactivation of pro-apoptotic signaling pathways [3, 4].”
BackgroundPD-1/PD-L1 and DNA Damage Response in Cancer
Kciuk, M., Kołat, D., Kałuzińska‐Kołat, Ż., Gawrysiak, M., Drozda, R., Çelik, İ., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040530 · Cited by 50
“Two factors are necessary for cisplatin to induce P73-dependent apoptosis: ABL tyrosine kinase activation and the cellular proficiency of the MMR repair pathway that connects damage sensing to apoptotic signaling [174].”
BackgroundCochlear pharmacokinetics of cisplatin: An in vivo study in the guinea pig
Hellberg, V., Wallin, I., Ehrsson, H., & Laurell, G. F. E. (2013) · The Laryngoscope · doi:10.1002/lary.24235 · Cited by 44
APC selectively mediates response to chemotherapeutic agents in breast cancer
VanKlompenberg, M. K., Bedalov, C. O., Soto, K. F., & Prosperi, J. R. (2015) · BMC Cancer · doi:10.1186/s12885-015-1456-x · Cited by 45
“and cisplatin are used at various stages (neoadjuvant, adjuvant, metastatic) to treat breast cancer [15–19], [20, 21].”
Down-regulation of ALKBH2 increases cisplatin sensitivity in H1299 lung cancer cells
Wu, S., Xu, W., Liu, S., Chen, B., Wang, X., Wang, Y., Liu, S.-F., & Wu, J. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.216 · Cited by 43
Itamochi, H., Nishimura, M., Oumi, N., Kato, M., Oishi, T., Shimada, M., Sato, S., Naniwa, J., Sato, S., Kudoh, A., et al. (2013) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000014 · Cited by 47
“ways, including ataxia telangiectasiajmutated (ATM) and ATM and Rad3-related (ATR) signaling pathways.(9,10) Serine/”
BackgroundEnhancing lipophilicity as a strategy to overcome resistance against platinum complexes?
Buß, I., Garmann, D., Galanski, M. S., Weber, G., Kalayda, G. V., Keppler, B. K., & Jaehde, U. (2011) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.02.005 · Cited by 44
Nanomodification of living organisms by biomimetic mineralization
Chen, W., Wang, G., & Tang, R. (2014) · Nano Research · doi:10.1007/s12274-014-0509-9 · Cited by 44
“However, it encounters the same fate as many other medicines used in therapy – namely, drug resistance [121], which is a major complication in chemotherapy and accounts for the failure in”
BackgroundHydrogen sulfide: A novel nephroprotectant against cisplatin-induced renal toxicity
Dugbartey, G. J., Bouma, H. R., Lobb, I., & Şener, A. (2016) · Nitric Oxide · doi:10.1016/j.niox.2016.04.005 · Cited by 44
“These include head and neck cancer, penile cancer, endometrial cancer, esophageal cancer, carcinoids, mesothelioma, non-small cell lung cancer, malignant melanoma, adrenocortical carcinoma, testicular cancer, ovarian cancer, breast cancer, as well as cervical and bladder cancer [1,2].”
BackgroundPerrotta, C., Buonanno, F., Zecchini, S., Giavazzi, A., Serafini, F. P., Catalani, E., Guerra, L., Belardinelli, M. C., Picchietti, S., Fausto, A. M., et al. (2016) · Scientific Reports · doi:10.1038/srep27281 · Cited by 44
Highly tumorigenic hepatocellular carcinoma cell line with cancer stem cell-like properties
Lacoste, B., Raymond, V., Cassim, S., Lapierre, P., & Bilodeau, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171215 · Cited by 46
Interactions of cisplatin and the copper transporter CTR1 in human colon cancer cells
Åkerfeldt, M. C., Tran, C. M.-N., Shen, C., Hambley, T. W., & New, E. J. (2017) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-017-1467-y · Cited by 44
Zhang, Y., Fan, J., Fan, Y., Li, L., He, X., Xiang, Q., Mu, J., Zhou, D., Sun, X., Yang, Y., et al. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0459-2 · Cited by 44
“Cisplatin is cell cycle phase-nonspecific chemotherapy drug [18].”
Malfatti, M. C., Gerratana, L., Dalla, E., Isola, M., Damante, G., Loreto, C. D., Puglisi, F., & Tell, G. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1294-9 · Cited by 49
Suenaga, N., Kuramitsu, M., Komure, K., Kanemaru, A., Takano, K., Ozeki, K., Nishimura, Y., Yoshida, R., Nakayama, H., Shinriki, S., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205194 · Cited by 46
“In contrast, it has been also reported that one of the mechanisms of cisplatin resistance is suppression of cisplatin-induced apoptosis in various types of malignant tumors [28,29].”
BackgroundInfluentialMicroRNAs as the critical regulators of cisplatin resistance in gastric tumor cells
Zangouei, A. S., & Moghbeli, M. (2021) · Genes and Environment · doi:10.1186/s41021-021-00192-4 · Cited by 45
Li, Z., Yao, Q., Tian, Y., Jiang, Y., Xu, M., Wang, H., Xiong, Y., Fang, J., Wen, L., Yu, D., et al. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114904 · Cited by 44
New-generation platinum drugs in the treatment of cisplatin-resistant cancers
McKeage, M. J. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.8.1033 · Cited by 44
Wang, Q. (2011) · Oncology Reports · doi:10.3892/or.2011.1405 · Cited by 50
Silencing of GLUT ‐1 inhibits sensitization of oral cancer cells to cisplatin during hypoxia
Shimanishi, M., Ogi, K., Sogabe, Y., Kaneko, T., Dehari, H., Miyazaki, A., & Hiratsuka, H. (2012) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12028 · Cited by 46
Biodegradable Passion Fruit-Like Nano-Architectures as Carriers for Cisplatin Prodrug
Cassano, D., Santi, M., Cappello, V., Luin, S., Signore, G., & Voliani, V. (2016) · Particle & Particle Systems Characterization · doi:10.1002/ppsc.201600175 · Cited by 43
Zhang, M., Luo, H., & Hui, L. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.03.203 · Cited by 44
miR-194-5p inhibits SLC40A1 expression to induce cisplatin resistance in ovarian cancer
Wu, J., Zhang, L., Wu, S., Yi, X., & Liu, Z. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.152979 · Cited by 46
Fan, Z., Xie, J., Sadhukhan, T., Liang, C., Huang, C., Li, W., Li, T., Zhang, P., Banerjee, S., Raghavachari, K., et al. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202103346 · Cited by 45
Advances in plant-derived natural products for antitumor immunotherapy
Yang, Y., Liu, Q., Shi, X., Zheng, Q., Chen, L., & Sun, Y. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-021-01355-1 · Cited by 48
“Fucoidan, a sulfated water-soluble polysaccharide extracted from brown seaweeds such as Undaria pinnatifida, is thought to be beneficial for patients with colorectal cancer, lung cancer, breast cancer and other cancers treated with chemotherapy (Siddik 2003; Wang and Lippard 2005; Liu et al.”
BackgroundDhivya, R., Jaividhya, P., Riyasdeen, A., Palaniandavar, M., Ganeshan, M., & Akbarsha, M. A. (2015) · BioMetals · doi:10.1007/s10534-015-9877-1 · Cited by 43
Mirtazapine protects against cisplatin‐induced oxidative stress and DNA damage in the rat brain
Güleç, M., Oral, E., Dursun, O. B., Yücel, A., Hacımüftüoğlu, A., Akçay, F., & Süleyman, H. (2012) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2012.02395.x · Cited by 55
Cheung-Ong, K., Song, K., Ma, Z., Shabtai, D., Lee, A. Y., Gallo, D., Heisler, L. E., Brown, G. W., Bierbach, U., Giaever, G. N., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb300320d · Cited by 47
Amatori, S., Bagaloni, I., Macedi, E., Formica, M., Giorgi, L., Fusi, V., & Fanelli, M. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605745 · Cited by 45
Alam, N., Khare, V. R., Dubey, R., Saneja, A., Kushwaha, M., Singh, G., Sharma, N., Chandan, B. K., & Gupta, P. N. (2014) · Materials Science and Engineering C · doi:10.1016/j.msec.2014.01.043 · Cited by 45
Illán‐Cabeza, N. A., Vilaplana, R. A., Alvarez, Y., Akdi, K., Kamah, S., Hueso‐Ureña, F., Quirós, M., González-Vı́lchez, F., & Moreno‐Carretero, M. N. (2005) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-005-0045-x · Cited by 44
The response of human ectomesenchymal dental pulp stem cells to cisplatin treatment
Seifrtová, M., Havelek, R., Ćmielová, J., Jiroutová, A., Soukup, T., Brůčková, L., Mokrý, J., English, D. K., & Řezáčová, M. (2011) · International Endodontic Journal · doi:10.1111/j.1365-2591.2011.01990.x · Cited by 44
da Silva, G. N., Marcondes, J. P. D. C., de Camargo, E. A., Passos, G. A. S., Sakamoto‐Hojo, E. T., & Salvadori, D. M. F. (2010) · Experimental Biology and Medicine · doi:10.1258/ebm.2010.009322 · Cited by 42
ASGAR, M. A., Senawong, G., Sripa, B., & Senawong, T. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3240 · Cited by 43
Theoretical Prediction of the Complexation Behaviors of Antitumor Platinum Drugs with Cucurbiturils
Venkataramanan, N. S., Suvitha, A., Mizuseki, H., & Kawazoe, Y. (2012) · The Journal of Physical Chemistry B · doi:10.1021/jp3098044 · Cited by 43
Wu, K., Tan, M., Jiang, J., Mu, X., Wang, J.-R., Zhou, W., Wang, X., Li, M., He, Y., & Liu, Z. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.01.012 · Cited by 45
Is it true that gut microbiota is considered as panacea in cancer therapy?
Farrokhi, A. S., Darabi, N., Yousefi, B., Askandar, R. H., Shariati, M., & Eslami, M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28333 · Cited by 45
“could stimulate apoptosis of tumor cells and cause DNA damage that results in the induction of proapoptotic pathways (Siddik, 2003).”
BackgroundHsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation
Pan, C., Chun, J., Li, D., Boese, A. C., Li, J., Kang, J., Umano, A. D., Jiang, Y., Song, L., Magliocca, K. R., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125963 · Cited by 45
“In addition, CHIP modulation consequently altered MEK and ERK phosphorylation levels when the cells were treated with cisplatin (Supplemental Figure 7, B and C).”
BackgroundInfluentialCao, L., Wang, X., Wang, Q., Xue, P., Jiao, X., Peng, H., Lu, H., Zheng, Q., Chen, X.-L., Huang, X., et al. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.119 · Cited by 44
Wang, H., Li, X., Chen, T., Wang, W., Liu, Q., Li, H., Yi, J., & Wang, J. (2012) · Oncology Reports · doi:10.3892/or.2012.2156 · Cited by 43
Wei, N., Liu, G.-T., Chen, X., Liu, Q., Wang, F., & Sun, H. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.08.012 · Cited by 43
Maimaitiyiming, H., Li, Y., Cui, W., Tong, X., Norman‐Burgdolf, H., Qi, X., & Wang, S. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00192.2013 · Cited by 44
“It is being used to treat a variety of solid tumors (5, 10, 14, 48).”
BackgroundSong, J., Shih, I., Salani, R., Chan, D. W., & Zhang, Z. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0569 · Cited by 43
SUMOylation occurs in acute kidney injury and plays a cytoprotective role
Guo, C., Wei, Q., Su, Y., & Dong, Z. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.12.013 · Cited by 44
Lin, M., Lin, S., Chen, J., Hui, C., & Chen, J.-Y. (2010) · Peptides · doi:10.1016/j.peptides.2010.02.023 · Cited by 42
Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells
Low, S. Y., Tan, B. S., Choo, H. L., Tiong, K. H., Khoo, A. S. B., & Leong, C. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.025 · Cited by 42
Structural insight into dynamic bypass of the major cisplatin‐DNA adduct by Y‐family polymerase Dpo4
Wong, J. H. Y., Brown, J. A., Suo, Z., Blum, P., Nohmi, T., & Ling, H. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.101 · Cited by 42
Suchi, K., Fujiwara, H., Okamura, S., Okamura, H., Umehara, S., Todo, M., Furutani, A., 米田, 政., Shiozaki, A., Kubota, T., et al. (2011) · PubMed · Cited by 42
Im, J., Lee, K.-W., Won, K., Kim, B., Ban, H. S., Yoon, S.-H., Lee, Y.-J., Kim, Y., Song, K., & Won, M. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.10.011 · Cited by 46
Ho, J.-N., Byun, S.-S., Lee, S., Oh, J. J., Hong, S. K., Lee, S. E., & Yeon, J. S. (2015) · Journal of Urology · doi:10.1016/j.juro.2014.09.007 · Cited by 42
Savaraj, N., Wu, C., Li, Y., Wangpaichitr, M., You, M., Bomalaski, J. S., He, W., Kuo, M. T., & Feun, L. G. (2015) · Oncotarget · doi:10.18632/oncotarget.3370 · Cited by 41
“We have chosen cisplatin, one of the most widely used chemotherapeutic agents in solid tumors, which is known to trigger apoptosis via the intrinsic pathway[16].”
Wang, J., Qiu, Z., Wang, Y., Li, L., Guo, X., Pham, D., Lincoln, S. F., & Prud’homme, R. K. (2016) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.12.7 · Cited by 44
DFT Investigation of the Mechanism of Action of Organoiridium(III) Complexes As Anticancer Agents
Ritacco, I., Russo, N., & Sicilia, E. (2015) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.5b01832 · Cited by 45
Triple Block Nanocarrier Platform for Synergistic Cancer Therapy of Antagonistic Drugs
Surnar, B., & Jayakannan, M. (2016) · Biomacromolecules · doi:10.1021/acs.biomac.6b01608 · Cited by 42
Roy, S., Böhme, M., Dash, S. P., Mohanty, M., Buchholz, A., Plass, W., Majumder, S., Kulanthaivel, S., Banerjee, I., Reuter, H., et al. (2018) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.8b00035 · Cited by 42
Role of epigenetic mechanisms in cisplatin-induced toxicity
Quintanilha, J. C. F., Saavedra, K., Visacri, M. B., Moriel, P., & Salazar, L. A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.03.004 · Cited by 47
Gd( iii )–Pt( iv ) theranostic contrast agents for tandem MR imaging and chemotherapy
Adams, C. J., & Meade, T. J. (2020) · Chemical Science · doi:10.1039/c9sc05937g · Cited by 45
Servidei, T., Riccardi, A., Mozzetti, S., Ferlini, C., & Riccardi, R. (2008) · International Journal of Cancer · doi:10.1002/ijc.23902 · Cited by 45
Platinum transporters and drug resistance
Choi, M., & Kim, D. (2006) · Archives of Pharmacal Research · doi:10.1007/bf02969293 · Cited by 42
Yarin, Y. M., Amarjargal, N., Fuchs, J., Haupt, H., Mazurek, B., Morozova, S. V., & Gross, J. (2004) · Hearing Research · doi:10.1016/j.heares.2004.09.015 · Cited by 42
Increased antitumor efficacy by the combined administration of swainsonine and cisplatin in vivo
Santos, F. M., Latorre, A. O., Hueza, I. M., Sanches, D. S., Lippi, L. L., Gardner, D. R., & Spinosa, H. D. S. (2011) · Phytomedicine · doi:10.1016/j.phymed.2011.06.005 · Cited by 43
Sharawy, N., Rashed, L. A., & Youakim, M. F. (2015) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2015.02.003 · Cited by 43
Jain, H. V., & Meyer‐Hermann, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-3174 · Cited by 41
API5 induces cisplatin resistance through FGFR signaling in human cancer cells
Jang, H. S., Woo, S. R., Song, K., Cho, H., Chay, D. B., Hong, S.-O., Lee, H., Oh, S. J., Chung, J., Kim, J., et al. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.130 · Cited by 41
Metadata
- Authors
- Siddik, Z. H.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Siddik, Zahid H
- ORCID
- Siddik, Zahid H
- Venue
- Oncogene
- Published
- 2003-10-20
- Volume
- 22
- Issue
- 47
- Pages
- 7265-7279
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2164277862
- Cited by
- 3,335
- References
- 154
- Citations by year
- 2026: 67 · 2025: 94 · 2024: 127 · 2023: 161 · 2022: 195 · 2021: 216 · 2020: 203 · 2019: 181 · 2018: 184 · 2017: 185 · 2016: 215 · 2015: 193 · 2014: 205 · 2013: 175 · 2012: 165
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca077332-03)
- National Cancer Institute (CA-77332, R01CA082361, CA 82361)
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- cisplatin, cisplatin resistance, DNA adducts, DNA cross-linking, apoptosis, ATR signaling, p53, p73, MAPK signaling, DNA damage response, drug uptake, drug inactivation, DNA repair, HER2/neu, PI3K/Akt signaling, Bcl-2, caspase activation, signal transduction
- MeSH terms
- Cisplatin, DNA Damage, DNA Repair, Humans, Tumor Suppressor Protein p53, Apoptosis, Drug Resistance, Neoplasm, MAP Kinase Signaling System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.